




Acyclic nucleoside phosphonates containing the amide bond

Iwona E. Głowacka¹ · Dorota G. Piotrowska¹ · Graciela Andrei² ·
Dominique Schols² · Robert Snoeck² · Andrzej E. Wróblewski¹Received: 7 June 2016 / Accepted: 4 September 2016 / Published online: 26 October 2016
© The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract To study the influence of a linker rigidity and donor–acceptor properties, the P–CH₂–O–CHR– fragment in acyclic nucleoside phosphonates (e.g., acyclovir, tenofovir) was replaced by the P–CH₂–HN–C(O)– residue. The respective phosphonates were synthesized in good yields by coupling the straight chain of *ω*-aminophosphonates and nucleobase-derived acetic acids with EDC. Based on the ¹H and ¹³C NMR data, the unrestricted rotation within the methylene and 1,2-ethylidene linkers in phosphonates from series **a** and **b** was confirmed. For phosphonates containing 1,3-propylidene (series **c**) fragments, antiperiplanar disposition of the bulky *O,O*-diethylphosphonate and substituted amidomethyl groups was established. The synthesized ANPs P–X–HNC(O)–CH₂B (X = CH₂, CH₂CH₂, CH₂–CH₂CH₂, CH₂OCH₂CH₂) appeared inactive in antiviral assays against a wide variety of DNA and RNA viruses at concentrations up to 100 μM while marginal antiproliferative activity (L1210 cells, IC₅₀ = 89 ± 16 μM and HeLa cells, IC₅₀ = 194 ± 19 μM) was noticed for the analog derived from (5-fluorouracyl-1-yl)acetic acid and *O,O*-diethyl (2-aminoethoxy)methylphosphonate.

Graphical abstract

**Keywords** Nucleotides · Amide bond formation · NMR spectroscopy · Phosphonates

Introduction

The search for new compounds endowed with antiviral activity has been underway for decades. Several research groups have been active in this field, both in academia and pharmaceutical industry. Despite these efforts, for many viruses efficient drugs have not been yet discovered. In addition, anticancer drugs available so far exhibit limited applicability. The high mutation rate observed for some viruses makes the issue highly complex. Within medications applied to treat viral infections, acyclic nucleoside phosphonates (ANPs) play an important role [1–3]. The prototype of the acyclic nucleoside phosphonates (ANPs), (*S*)-HPMPA (**3**), was never commercialized but it gave rise to three marketed products [cidofovir (**4**), adefovir (**1**), and tenofovir (**2**)] that are often prescribed by physicians. So far known structural modifications of compounds **1–4** accomplished within a chain connecting nucleobase and phosphonic acid moieties did not lead to discovery of analogs having higher antiviral activity (Fig. 1).

Analysis of the mechanism of action of ANPs [3, 4] allows to conclude that within structures of newly designed

✉ Andrzej E. Wróblewski
andrzej.wroblewski@umed.lodz.pl¹ Bioorganic Chemistry Laboratory, Faculty of Pharmacy, Medical University of Lodz, Muszyńskiego 1, 90-151 Lodz, Poland² Rega Institute for Medical Research, KU Leuven, Minderbroedersstraat 10, 3000 Louvain, Belgium




Fig. 1 Acyclic nucleotide analogs 1–4

analogues of ANPs, the following fragments have to be installed: (1) a phosphonate unit (P–CH₂) which prevents enzymatic hydrolysis of the P–O bond present in natural phosphates, while being capable of further phosphorylation; (2) canonical nucleobases or their very close structurally heterocyclic systems to assure efficient interactions with the complementary nucleobases of the other polynucleotide chain; (3) a linker to adjust a distance between a nucleobase and a phosphorus atom which should contain four atoms considered optimal at this moment.

Taking into account high antiviral activity of compounds 1–4, one may be interested in specific interactions of oxygen lone pairs and also of the entire phosphonomethoxy (P–CH₂–O) fragment. The oxygen atom located within a P–CH₂–O–CHR– fragment can serve as a lone pair donor in intermolecular interactions, and single bonds connecting atoms in the linker ensure free rotation. To modify interactions of atoms located in the linker it is reasonable to consider replacing selected fragments of the linker for another moiety.

During studies on biological activity of peptides, replacements of the amide [–C(O)–NH–] residue for several isosteric fragments (including a methylene ether [–CH₂–O–] moiety) are commonly applied [5–7]. This particular replacement allows to preserve steric conformity of both bonding systems but essentially influences donor–acceptor interactions and possibilities of a rotation around the specific bonds within the linker [completely free around the CH₂–O bond (11.3 kJ/mol—barrier to rotation) as

compared to the hindered around the C(O)–NH bond (88 kJ/mol—barrier to rotation)]. In general, this isosteric replacement diminishes affinity of modified peptides in comparison with the natural ones.

The proposed structural modification of ANPs 1–4 relies on the incorporation of a specific fragment which will be able to increase donor–acceptor interactions within the linker. In our first approach, the [P–CH₂–O–CHR–] fragment will be replaced with the amide [P–CH₂–HN–C(O)–] residue to provide amides 5 (Scheme 1). In addition, a part of the linker containing the amide bond becomes rigid and thus may influence the activity of modified ANPs.


Several decades ago, a concept of phosphonate peptide nucleic acids (PPNA) was introduced [8–11] and a variety of related monomers 6 were synthesized, however, limited to aminomethyl- and aminoethylphosphonate derivatives. Our interest in the synthesis of phosphonates of general formula 5 significantly extends structural diversity of potential new monomers 6 primarily in the aminoalkylphosphonate fragment.

Herein, we wish to describe our studies on the synthesis and the biological activity of the amides 5. The synthetic strategy involves the formation of the amide bond from the respective acetic acid derivatives 8 and ω-aminophosphonates 7 (Scheme 1).

Results and discussion

To synthesize the first series of the amides 5, ω-aminophosphonates 7a–7d containing straight chain linkers were selected (Scheme 2). The ω-aminophosphonates 7a–7d were prepared according to the described procedures [12–14]. Among them, aminomethylphosphonate 7a was considered as the most important since it was later transformed into the analogs 17a–24a in which nitrogen atoms (N1 or N9) in nucleobases and the phosphorus atom are separated by four bonds, thus providing compounds structurally closest to the drugs 1–4.

Uracil (9)-, 5-fluorouracil (10)-, 5-bromouracil (11)-, thymine (12)-, and benzouracil (14)-containing acetic acids



(X = linker; B = canonical nucleobase; B' = nucleobase analogue)

Table 1 Optimization of the reaction conditions

Coupling reagent	Additive	Solvent	Time/temp.	Yield/%	Procedure
T3P	TEA	DMF	24 h/r.t.	40	A
EDC	TEA	DMF	72 h/r.t.	60	B
EDC	TEA	CHCl ₃	48 h/r.t.	62	B
EDC	TEA	CHCl ₃	15 min, 1 h/35 °C, 100 W	62	C

with nucleobase-substituted acetic acids **9–16** in the presence of EDC proceeded almost quantitatively. However, the final products **17a–24d** were isolated in moderate yields since several crystallizations were necessary to remove the last traces of triethylamine hydrochloride.


The guanine-containing phosphonates **25a–25d** were prepared from the 6-chloropurine precursors **24a–24d** by hydrolysis in acidic medium (Scheme 3) [34].

Conformational analysis

We also aimed to study the conformational behavior of an acyclic linker connecting a phosphorus atom and the amide nitrogen for future structure–activity considerations. Free rotation around P–CH₂ and H₂C–NH bonds in phosphonates **17a–25a**, as depicted by **26a** in Fig. 2, is evidenced from the vicinal *HNCH* couplings of 5.9 Hz observed in the spectra of **21a** and **25a** taken in chloroform-*d* and DMSO-*d*₆, respectively. In solutions in these solvents as well as in methanol-*d*₄ H₂CP are equivalent since they always appeared as a one doublet from two-bond HP coupling of 11.8 Hz.

Structure **26b** (Fig. 2) summarizes conformational flexibility of phosphonates **17b–25b** which is proved by the observation of the vicinal H₂C–CH₂ couplings of 7.6 Hz.

Since ¹³C NMR spectra of phosphonates **17c–25c** showed large values (18.1–19.6 Hz) of vicinal PCCC couplings, the antiperiplanar disposition of the P–CC–CH₂ groups is proposed and represented by the Newman projection **26c**.

**Fig. 2** Conformations of phosphonates discussed in this paper

Although significant values (11.0–12.1 Hz) were observed in the ¹³C NMR spectra of phosphonates **17d–25d** for vicinal PCOC couplings, they cannot be applied with confidence to discuss conformational behavior of the –CH₂OCH₂CH₂– linkage since the angular dependence within a P–C–O–C framework has not yet been established.

Antiviral activity

All phosphonates **17–25** were evaluated for inhibitory activity against a wide variety of DNA and RNA viruses, using the following cell-based assays: (a) human embryonic lung (HEL) cells: herpes simplex virus-1 (KOS strain), herpes simplex virus-2 (G strain), thymidine kinase-deficient (acyclovir resistant) herpes simplex virus-1 (TK[−] KOS ACV^r strain), vaccinia virus, adenovirus-2, vesicular stomatitis virus, cytomegalovirus (AD-169 strain and Davis strain), varicella-zoster virus (TK⁺ VZV strain and TK[−] VZV strain); (b) HeLa cell cultures: vesicular stomatitis virus, Coxsackie virus B4 and respiratory syncytial virus; (c) Vero cell cultures: parainfluenza-3 virus, reovirus-1, Sindbis virus, Coxsackie virus B4, Punta Toro virus, yellow fever virus; (d) CrFK cell cultures: feline corona virus (FIPV) and feline herpes virus (FHV); (e) MDCK cell cultures: influenza A virus (H1N1 and H3N2 subtypes) and influenza B virus. Ganciclovir, cidofovir, acyclovir, brivudine, zalcitabine, zanamivir, alovudine, amantadine, rimantadine, ribavirin, dextran sulfate (molecular weight 10,000, DS-10000), mycophenolic acid, Hipppeastrum hybrid agglutinin (HHA) and Urtica dioica agglutinin (UDA) were used as the reference compounds. The antiviral activity was expressed as the EC₅₀: the compound concentration required to reduce virus plaque formation (VZV) by 50% or to reduce virus-induced cytopathogenicity by 50% (other viruses). None of the tested compounds showed appreciable antiviral activity toward any of the tested DNA and RNA viruses at concentrations up to 100 μM, nor affected cell morphology of HEL, HeLa, Vero, MDCL, and CrFK cells.

Cytostatic activity

The 50% cytostatic inhibitory concentration (IC₅₀) causing a 50% decrease in cell proliferation was determined against




Fig. 3 Active derivatives of 5-fluorouracil

murine leukemia L1210, human lymphocyte CEM, human cervix carcinoma HeLa, and human dermal microvascular endothelial cells (HMEC-1).

Among all tested compounds, only phosphonate **18d** showed slight antiproliferative activity toward L1210 ($IC_{50} = 89 \pm 16 \mu M$) and HeLa cells ($IC_{50} = 194 \pm 19 \mu M$) and thus enlarges a collection of 5-fluorouracil derivatives which together with the parent compound have been widely clinically applied in therapies of various cancers [35]. Furthermore, the closest structural analog of **18d** (compound **18e**) was found active in vitro against L1210 cells at concentration of $15 \mu M$ [36] (Fig. 3).

Conclusion

Replacement of the P-CH₂-O-CHR- fragment in ANPs (e.g., acyclovir, tenofovir) by the P-CH₂-HN-C(O)- residue was introduced to study the influence of a linker rigidity and changes in donor-acceptor properties. To elaborate an appropriate synthetic methodology, a series of the 36 respective phosphonates as *O,O*-diethyl esters was prepared in good yields by the EDC-induced coupling of the straight chain ω -aminophosphonates and nucleobase-derived acetic acids. Besides the rigidity of the amide bond based on the ¹H and ¹³C NMR data, it was concluded that the unrestricted rotation within the methylene (series **a**) and 1,2-ethyldiene (series **b**) linkers takes place while for phosphonates containing 1,3-propylidene (series **c**) fragments antiperiplanar disposition of the bulky *O,O*-diethylphosphonate and substituted amidomethyl groups was observed. The phosphonates **17a–25d** appeared inactive in antiviral assays against a wide variety of DNA and RNA viruses at concentrations up to $100 \mu M$. Marginal antiproliferative activity (L1210, $IC_{50} = 89 \pm 16 \mu M$ and HeLa, $IC_{50} = 194 \pm 19 \mu M$) was noticed for the phosphonate **18d** derived from (5-fluorouracyl-1-yl)acetic acid and *O,O*-diethyl (2-aminoethoxy)methylphosphonate. Studies on the analogous phosphonates containing functionalized linkages are currently ongoing in our laboratory and the most active diethyl esters will be transformed into

the free ANP and further derivatized to selected prodrug phosphonates [37].

Experimental

¹H NMR spectra were recorded in CD₃OD, CDCl₃, or DMSO-*d*₆ on the following spectrometers: Varian Gemini 2000BB (200 MHz) and Bruker Avance III (600 MHz) with TMS as internal standard. ¹³C NMR spectra were recorded for CD₃OD, CDCl₃, or DMSO-*d*₆ solution on the Bruker Avance III at 151.0 MHz. ³¹P NMR spectra were performed on the Varian Gemini 2000BB at 81.0 MHz or on Bruker Avance III at 243.0 MHz. IR spectral data were measured on a Bruker Alpha-T FT-IR spectrometer. Melting points were determined on a Boetius apparatus. Elemental analyses were performed by Microanalytical Laboratory of this Faculty on Perkin Elmer PE 2400 CHNS analyzer and their results were found to be in good agreement ($\pm 0.3\%$) with the calculated values.

The following absorbents were used: column chromatography, Merck silica gel 60 (70–230 mesh); analytical TLC, Merck TLC plastic sheets silica gel 60 F₂₅₄. TLC plates were developed in chloroform–methanol solvent systems. Visualization of spots was effected with iodine vapors. All solvents were purified by methods described in the literature.

Synthesis of amides 17–24

General procedure A

A solution of 0.100 g aminophosphonate **7a** (0.598 mmol) in 2 cm³ DMF containing 0.100 g (thymine-1-yl)acetic acid (**12**, 0.544 mmol) was cooled to 0 °C and 0.152 cm³ TEA (1.09 mmol) followed by a 0.481 cm³ of a 50% solution of T3P[®] in DMF (0.816 mmol) were added. The reaction mixture was stirred at room temperature for 24 h, concentrated in vacuo and treated with 5 cm³ water. A solid was filtered off, air dried, and subjected to chromatography on a silica gel column with chloroform–methanol mixtures (20:1, 10:1 v/v) to give pure compound **20a** (0.072 g, 40% yield) as a white powder.

General procedure B

To a solution of aminophosphonates **7a–7d** (1.00 mmol) in 2 cm³ DMF or chloroform the respective acetic acids **9–16** (1.00 mmol), EDC \times HCl (1.00 mmol), and TEA (1.00 mmol) were added. The reaction mixture was stirred at room temperature for 48–72 h and then concentrated in vacuo. The residue was chromatographed on a silica gel column with chloroform–methanol mixtures and crystallized from the appropriate solvents.

General procedure C

To a solution of aminophosphonates **7a–7d** (1.00 mmol) in 2 cm³ chloroform the respective acetic acids **9–16** (1.00 mmol), EDC × HCl (1.00 mmol), and TEA (1.00 mmol) were added. The reaction mixture was irradiated (100 W) at 35 °C for the specified time (15 min–3 h) and then concentrated in vacuo. The residue was chromatographed on a silica gel column with chloroform–methanol mixtures and crystallized from the appropriate solvents.

Diethyl [2-(3,4-dihydro-2,4-dioxypyrimidin-1(2H)-yl)acetamido]methylphosphonate (**17a**, C₁₁H₁₈N₃O₆P)

The crude product obtained from 0.100 g diethyl 2-aminomethylphosphonate (**7a**, 0.60 mmol) and 0.097 g (uracil-1-yl)acetic acid (**9**, 0.60 mmol) in the presence of 0.115 g EDC × HCl (0.60 mmol) and 0.083 cm³ TEA (0.60 mmol) according to the general procedure B was chromatographed with chloroform–methanol mixtures (50:1, 20:1 v/v) to give pure compound **17a** (0.106 g, 55% yield) as a white powder. M.p.: 215–217 °C; IR (KBr): $\bar{\nu}$ = 3254, 3058, 2997, 2882, 2831, 1703, 1679, 1259, 1193, 1031 cm⁻¹; ¹H NMR (200 MHz, CD₃OD): δ = 7.56 (d, ³J = 7.9 Hz, 1H, HC6), 5.71 (d, ³J = 7.9 Hz, 1H, HC5), 4.51 (d, ³J = 1.4 Hz, 2H, C(O)CH₂), 4.26–4.11 (m, 4H, 2 × POCH₂CH₃), 3.78 (d, ²J = 11.8 Hz, 2H, PCH₂N), 1.37 (t, J = 7.0 Hz, 6H, 2 × POCH₂CH₃) ppm; ¹³C NMR (151 MHz, CD₃OD): δ = 167.92 (d, J = 3.7 Hz), 165.38, 151.36, 146.37, 100.85, 62.79 (d, J = 6.5 Hz, POC), 49.56, 34.23 (d, J = 158.5 Hz, PC), 15.28 (d, J = 5.8 Hz, POCC) ppm; ³¹P NMR (243 MHz, CD₃OD): δ = 23.6 ppm.

Diethyl 2-[2-(3,4-dihydro-2,4-dioxypyrimidin-1(2H)-yl)acetamido]ethylphosphonate (**17b**, C₁₂H₂₀N₃O₆P)

The crude product obtained from 0.100 g diethyl 2-aminoethylphosphonate (**7b**, 0.550 mmol) and 0.094 g (uracil-1-yl)acetic acid (**9**, 0.55 mmol) in the presence of 0.105 g EDC × HCl (0.550 mmol) and 0.077 cm³ TEA (0.55 mmol) according to the general procedure B was chromatographed with chloroform–methanol mixtures (50:1, 20:1 v/v) to give pure compound **17b** (0.095 g, 52% yield) as a white powder. M.p.: 138–140 °C; IR (KBr): $\bar{\nu}$ = 3340, 2986, 2953, 2896, 2826, 1696, 1673, 1236, 1024 cm⁻¹; ¹H NMR (600 MHz, CD₃OD): δ = 7.52 (d, ³J = 7.9 Hz, 1H, HC6), 5.70 (d, ³J = 7.9 Hz, 1H, HC5), 4.43 (s, 2H, C(O)CH₂), 4.18–4.10 (m, 4H, 2 × POCH₂CH₃), 3.48 (dt, J = 12.3 Hz, J = 7.6 Hz, 2H, PCH₂CH₂), 2.10 (dt, J = 15.3 Hz, J = 7.6 Hz, 2H, PCH₂), 1.36 (t, J = 7.1 Hz, 6H, 2 × POCH₂CH₃) ppm; ¹³C NMR (151 MHz, CD₃OD): δ = 167.92, 165.38, 151.49, 146.38, 100.95, 62.09 (d, J = 6.5 Hz, POC), 49.81, 33.41, 24.87 (d, J = 139.0 Hz, PC), 15.31 (d, J = 6.2 Hz, POCC) ppm; ³¹P NMR (243 MHz, CD₃OD): δ = 29.34 ppm.

Diethyl 3-[2-(3,4-dihydro-2,4-dioxypyrimidin-1(2H)-yl)acetamido]propylphosphonate (**17c**, C₁₃H₂₂N₃O₆P × H₂O)

The crude product obtained from 0.080 g diethyl 3-aminopropylphosphonate (**7c**, 0.41 mmol) and 0.070 g (uracil-1-yl)acetic acid (**9**, 0.41 mmol) in the presence of 0.079 g EDC × HCl (0.41 mmol) and 0.057 cm³ TEA (0.41 mmol) according to the general procedure B was chromatographed with chloroform–methanol mixtures (50:1, 20:1 v/v) and the selected fractions were crystallized from ethyl acetate to give pure compound **17c** (0.046 g, 32% yield) as a white solid. M.p.: 120–122 °C; IR (KBr): $\bar{\nu}$ = 3327, 3101, 2989, 2937, 2885, 2835, 1697, 1670, 1563, 1240, 1039 cm⁻¹; ¹H NMR (200 MHz, CD₃OD): δ = 7.56 (d, ³J = 7.9 Hz, 1H, HC6), 5.70 (d, ³J = 7.9 Hz, 1H, HC5), 4.45 (s, 2H, C(O)CH₂), 4.28–4.03 (m, 4H, 2 × POCH₂CH₃), 3.30 (t, J = 6.9 Hz, 2H, PCH₂CH₂CH₂), 1.95–1.68 (m, 4H, PCH₂CH₂), 1.36 (t, J = 7.1 Hz, 6H, 2 × POCH₂CH₃) ppm; ¹³C NMR (151 MHz, CD₃OD): δ = 168.08, 165.41, 151.44, 146.46, 100.85, 61.90 (d, J = 6.0 Hz, POC), 50.00, 39.34 (d, J = 18.8 Hz, PCCC), 22.13 (d, J = 4.5 Hz, PCC), 21.91 (d, J = 142.1 Hz, PC), 15.30 (d, J = 5.7 Hz, POCC) ppm; ³¹P NMR (81 MHz, CD₃OD): δ = 33.69 ppm.

Diethyl [2-[2-(3,4-dihydro-2,4-dioxypyrimidin-1(2H)-yl)acetamido]ethoxy]methyl phosphonate (**17d**, C₁₃H₂₂N₃O₇P)

The crude product obtained from 0.050 g diethyl (2-aminoethoxy)methylphosphonate (**7d**, 0.237 mmol) and 0.040 g (uracil-1-yl)acetic acid (**9**, 0.237 mmol) in the presence of 0.045 g EDC × HCl (0.237 mmol) and 0.033 cm³ TEA (0.237 mmol) according to the general procedure B was chromatographed with chloroform–methanol mixtures (50:1, 20:1 v/v) and the selected fractions were crystallized from ethyl acetate–hexane mixture to give pure compound **17d** (0.060 g, 70% yield) as white needles. M.p.: 116–117 °C; IR (KBr): $\bar{\nu}$ = 3320, 3098, 2984, 2980, 2951, 2888, 2821, 1695, 1673, 1257, 1031 cm⁻¹; ¹H NMR (200 MHz, CD₃OD): δ = 7.56 (d, ³J = 7.9 Hz, 1H, HC6), 5.70 (d, ³J = 7.9 Hz, 1H, HC5), 4.48 (s, 2H, C(O)CH₂), 4.29–4.14 (m, 4H, 2 × POCH₂CH₃), 3.92 (d, J = 8.5 Hz, 2H, PCH₂O), 3.69 (t, J = 5.3 Hz, 2H, PCH₂OCH₂CH₂), 3.46 (t, J = 5.3 Hz, 2H, PCH₂OCH₂CH₂), 1.38 (t, J = 7.0 Hz, 6H, 2 × POCH₂CH₃) ppm; ¹³C NMR (151 MHz, CD₃OD): δ = 168.04, 165.39, 151.44, 146.44, 100.83, 71.44 (d, J = 12.1 Hz, PCOC), 64.19 (d, J = 166.9 Hz, PC), 62.77 (d, J = 6.6 Hz, POC), 49.70, 38.96, 15.36 (d, J = 5.5 Hz, POCC) ppm; ³¹P NMR (81 MHz, CD₃OD): δ = 23.10 ppm.

*Diethyl [2-(5-fluoro-3,4-dihydro-2,4-dioxypyrimidin-1(2H)-yl)acetamido]methylphosphonate***(18a)**, C₁₁H₁₇FN₃O₆P × 0.5H₂O

The crude product obtained from 0.107 g diethyl aminomethylphosphonate (**7a**, 0.640 mmol) and 0.120 g (5-fluorouracil-1-yl)acetic acid (**10**, 0.640 mmol) in the presence of 0.123 g EDC × HCl (0.640 mmol) and 0.089 cm³ TEA (0.64 mmol) according to the general procedure B was filtered and crystallized from a methanol–diethyl ether mixture to give pure compound **18a** (0.127 g, 59% yield) as a white powder. M.p.: 205–208 °C; IR (KBr): $\bar{\nu}$ = 3224, 3061, 3000, 2941, 2830, 1738, 1700, 1034 cm⁻¹; ¹H NMR (600 MHz, CD₃OD): δ = 7.80 (d, *J* = 6.2 Hz, 1H, HC6), 4.46 (s, 2H, C(O)CH₂), 4.20–4.15 (m, 4H, 2 × POCH₂CH₃), 3.76 (d, *J* = 11.8 Hz, 2H, PCH₂), 1.36 (t, *J* = 7.1 Hz, 6H, 2 × POCH₂CH₃) ppm; ¹³C NMR (151 MHz, CD₃OD): δ = 167.78 (d, ³*J* = 3.2 Hz, C(O)NHCP), 158.54 (d, *J* = 26.2 Hz), 150.12, 140.17 (d, *J* = 232.5 Hz), 130.30 (d, *J* = 34.1 Hz), 62.82 (d, *J* = 6.0 Hz, POC), 49.56, 34.27 (d, *J* = 158.6 Hz, PC), 15.28 (d, *J* = 5.8 Hz, POCC) ppm; ³¹P NMR (273 MHz, CD₃OD): δ = 22.71 ppm.

*Diethyl 2-[2-(5-fluoro-3,4-dihydro-2,4-dioxypyrimidin-1(2H)-yl)acetamido]ethylphosphonate***(18b)**, C₁₂H₁₉FN₃O₆P

The crude product obtained from 0.114 g diethyl 2-aminoethylphosphonate (**7b**, 0.629 mmol) and 0.118 g (5-fluorouracil-1-yl)acetic acid (**10**, 0.629 mmol) in the presence of 0.121 g EDC × HCl (0.629 mmol) and 0.088 cm³ TEA (0.63 mmol) according to the general procedure B was chromatographed with chloroform–methanol mixtures (100:1, 50:1, 20:1 v/v) and the selected fractions were crystallized from a methanol–diethyl ether mixture to give pure compound **18b** (0.131 g, 59% yield) as a white solid. M.p.: 185–186 °C; IR (KBr): $\bar{\nu}$ = 3241, 3063, 3035, 2982, 2930, 1742, 1657, 1630, 1215, 1056 cm⁻¹; ¹H NMR (600 MHz, CD₃OD): δ = 7.80 (d, *J* = 6.2 Hz, 1H, HC6), 4.41 (s, 2H, C(O)CH₂), 4.19–4.10 (m, 4H, 2 × POCH₂CH₃), 3.51–3.46 (m, 2H, PCH₂CH₂), 2.13–2.08 (m, 2H, 2H, PCH₂), 1.36 (t, *J* = 7.1 Hz, 3H, POCH₂CH₃) ppm; ¹³C NMR (151 MHz, CD₃OD): δ = 167.76, 158.53 (d, *J* = 25.6 Hz), 150.19, 140.24 (d, *J* = 231.0 Hz), 130.27 (d, *J* = 34.1 Hz), 62.07 (d, *J* = 6.6 Hz, POC), 49.78, 33.40 (d, *J* = 1.6 Hz), 24.86 (d, *J* = 139.6 Hz, PC), 15.28 (d, *J* = 5.7 Hz, POCC) ppm; ³¹P NMR (243 MHz, CD₃OD): δ = 29.30 ppm.

*Diethyl 3-[2-(5-fluoro-3,4-dihydro-2,4-dioxypyrimidin-1(2H)-yl)acetamido]propylphosphonate***(18c)**, C₁₃H₂₁FN₃O₆P × 0.5H₂O

The crude product obtained from 0.055 g diethyl 3-aminopropylphosphonate (**7c**, 0.28 mmol) and 0.053 g (5-fluorouracil-1-yl)acetic acid (**10**, 0.28 mmol) in the

presence of 0.054 g EDC × HCl (0.28 mmol) and 0.040 cm³ TEA (0.28 mmol) according to the general procedure B was chromatographed with chloroform–methanol mixtures (50:1, 20:1 v/v) and the selected fractions were crystallized from a methanol–diethyl ether mixture to give pure compound **18c** (0.048 g, 47% yield) as a white solid. M.p.: 143–144 °C; IR (KBr): $\bar{\nu}$ = 3240, 3096, 3032, 2996, 2955, 2940, 2884, 2835, 1740, 1669, 1677, 1240, 1033 cm⁻¹; ¹H NMR (600 MHz, CD₃OD): δ = 7.81 (d, *J* = 6.3 Hz, 1H, HC6), 4.40 (s, 2H, C(O)CH₂), 4.17–4.07 (m, 4H, 2 × POCH₂CH₃), 3.33 (t, *J* = 6.4 Hz, 2H, PCH₂CH₂CH₂), 1.88–1.77 (m, 4H, PCH₂CH₂), 1.35 (t, *J* = 7.0 Hz, 6H, 2 × POCH₂CH₃) ppm; ¹³C NMR (151 MHz, CD₃OD): δ = 167.91, 158.58 (d, *J* = 25.7 Hz), 150.18, 140.20 (d, *J* = 232.5 Hz), 130.40 (d, *J* = 33.2 Hz), 61.90 (d, *J* = 6.6 Hz, POC), 50.01, 39.36 (d, *J* = 18.7 Hz, PCCC), 22.11 (d, *J* = 3.9 Hz, PCC), 21.91 (d, *J* = 141.9 Hz, PC), 15.32 (d, *J* = 5.7 Hz, POCC) ppm; ³¹P NMR (243 MHz, CD₃OD): δ = 32.80 ppm.

*Diethyl 2-[2-(5-fluoro-3,4-dihydro-2,4-dioxypyrimidin-1(2H)-yl)acetamido]ethoxy]methylphosphonate***(18d)**, C₁₃H₂₁FN₃O₇P

The crude product obtained from 0.076 g diethyl 3-aminopropylphosphonate (**18d**, 0.360 mmol) and 0.068 g (5-fluorouracil-1-yl)acetic acid (**10**, 0.36 mmol) in the presence of 0.069 g EDC × HCl (0.36 mmol) and 0.050 cm³ TEA (0.360 mmol) according to the general procedure B was chromatographed with chloroform–methanol mixtures (50:1, 20:1 v/v) and the selected fractions were crystallized from ethyl acetate to give pure compound **18d** (0.83 g, 61% yield) as a white solid. M.p.: 69–70 °C; IR (KBr): $\bar{\nu}$ = 3362, 3169, 3058, 2995, 2933, 2825, 1699, 1662, 1242, 1024, 974 cm⁻¹; ¹H NMR (200 MHz, CD₃OD): δ = 7.83 (d, *J* = 6.2 Hz, 1H, HC6), 4.44 (s, 2H, C(O)CH₂), 4.29–4.14 (m, 4H, 2 × POCH₂CH₃), 3.92 (d, *J* = 8.5 Hz, 2H, PCH₂O), 3.70 (t, *J* = 5.3 Hz, 2H, PCH₂OCH₂CH₂), 3.46 (t, *J* = 5.3 Hz, 2H, PCOCH₂CH₂), 1.38 (t, *J* = 7.1 Hz, 6H, 2 × POCH₂CH₃) ppm; ¹³C NMR (151 MHz, CD₃OD): δ = 167.89, 158.09 (d, *J* = 25.7 Hz), 150.18, 140.19 (d, *J* = 232.5 Hz), 130.36 (d, *J* = 33.2 Hz), 71.43 (d, *J* = 12.1 Hz, PCOC), 64.18 (d, *J* = 167.6 Hz, PC), 62.79 (d, *J* = 6.6 Hz, POC), 49.70, 38.97, 15.36 (d, *J* = 5.6 Hz, POCC) ppm; ³¹P NMR (81 MHz, CD₃OD): δ = 23.11 ppm.

*Diethyl [2-(5-bromo-3,4-dihydro-2,4-dioxypyrimidin-1(2H)-yl)acetamido]methylphosphonate***(19a)**, C₁₁H₁₇BrN₃O₆P

The crude product obtained from 0.099 g diethyl aminomethylphosphonate (**7a**, 0.59 mmol) and 0.088 g (5-bromouracil-1-yl)acetic acid (**11**, 0.59 mmol) in the

presence of 0.114 g EDC \times HCl (0.592 mmol) and 0.083 cm³ TEA (0.59 mmol) according to the general procedure B was chromatographed with chloroform–methanol mixtures (50:1, 20:1 v/v) and the selected fractions were crystallized from an ethanol–diethyl ether mixture to give pure compound **19a** (0.094 g, 40% yield) as a white solid. M.p.: 211–213 °C; IR (KBr): $\bar{\nu}$ = 3225, 3065, 2992, 2941, 2830, 1698, 1680, 1024, 623 cm⁻¹; ¹H NMR (200 MHz, CD₃OD): δ = 8.04 (s, 1H, HC6), 4.53 (d, J = 1.5 Hz, 2H, C(O)CH₂), 4.26–4.11 (m, 4H, 2 \times POCH₂CH₃), 3.78 (d, J = 11.8 Hz, 2H, PCH₂), 1.37 (t, J = 7.1 Hz, 6H, 2 \times POCH₂CH₃) ppm; ¹³C NMR (151 MHz, CD₃OD): δ = 167.70 (d, J = 3.6 Hz), 160.72, 150.80, 145.79, 95.09, 62.83 (d, J = 6.0 Hz, POC), 49.60, 34.27 (d, J = 158.6 Hz, PC), 15.29 (d, J = 5.7 Hz, POCC) ppm; ³¹P NMR (273 MHz, CD₃OD): δ = 22.70 ppm.

Diethyl 2-[2-(5-bromo-3,4-dihydro-2,4-dioxypyrimidin-1(2H)-yl)acetamido]ethylphosphonate
(**19b**, C₁₂H₁₉BrN₃O₆P)

The crude product obtained from 0.078 g diethyl 2-aminoethylphosphonate (**7b**, 0.431 mmol) and 0.107 g (5-bromouracil-1-yl)acetic acid (**11**, 0.431 mmol) in the presence of 0.083 g EDC \times HCl (0.431 mmol) and 0.060 cm³ TEA (0.431 mmol) according to the general procedure B was chromatographed with chloroform–methanol mixtures (100:1, 50:1, 20:1 v/v) and the selected fractions were crystallized from ethyl acetate to give pure compound **19b** (0.082 g, 46% yield) as white needles. M.p.: 211–213 °C; IR (KBr): $\bar{\nu}$ = 3224, 3164, 3067, 2994, 2822, 1708, 1680, 1216, 1019, 619 cm⁻¹; ¹H NMR (200 MHz, CD₃OD): δ = 8.04 (s, 1H, HC6), 4.46 (s, 2H, C(O)CH₂), 4.24–4.07 (m, 4H, 2 \times POCH₂CH₃), 3.56–3.43 (m, 2H, PCH₂CH₂), 2.20–2.04 (m, 2H, 2H, PCH₂), 1.38 (t, J = 7.1 Hz, 3H, POCH₂CH₃) ppm; ¹³C NMR (151 MHz, CD₃OD): δ = 167.68, 160.72, 150.89, 145.78, 95.17, 62.09 (d, J = 6.6 Hz, POC), 49.83, 33.43 (d, J = 1.7 Hz), 24.86 (d, J = 139.5 Hz, PC), 15.29 (d, J = 5.7 Hz, POCC) ppm; ³¹P NMR (81 MHz, CD₃OD): δ = 30.20 ppm.

Diethyl 3-[2-(5-bromo-3,4-dihydro-2,4-dioxypyrimidin-1(2H)-yl)acetamido]propylphosphonate
(**19c**, C₁₃H₂₁BrN₃O₆P)

The crude product obtained from 0.151 g diethyl 3-aminopropylphosphonate (**7c**, 0.774 mmol) and 0.115 g (5-bromouracil-1-yl)acetic acid (**11**, 0.774 mmol) in the presence of 0.148 g EDC \times HCl (0.774 mmol) and 0.108 cm³ TEA (0.774 mmol) according to the general procedure B was chromatographed with dichloromethane–methanol mixtures (100:1, 50:1, 20:1 v/v) and the selected fractions were crystallized from a methanol–diethyl ether mixture to give pure compound **19c** (0.063 g, 20% yield) as a white solid. M.p.: 164–166 °C; IR (KBr): $\bar{\nu}$ = 3259,

3039, 2830, 2835, 1720, 1681, 1235, 1033 cm⁻¹; ¹H NMR (600 MHz, CD₃OD): δ = 8.05 (s, 1H, HC6), 4.46 (s, 2H, C(O)CH₂), 4.21–4.04 (m, 4H, 2 \times POCH₂CH₃), 3.33 (t, J = 6.4 Hz, 2H, PCH₂CH₂CH₂), 1.98–1.72 (m, 4H, PCH₂CH₂), 1.36 (t, J = 7.0 Hz, 6H, 2 \times POCH₂CH₃) ppm; ¹³C NMR (151 MHz, CD₃OD): δ = 167.84, 160.77, 150.87, 145.88, 95.09, 61.89 (d, J = 6.6 Hz, POC), 50.05, 39.36 (d, J = 18.7 Hz, PCCC), 22.09 (d, J = 4.7 Hz, PCC), 21.90 (d, J = 141.9 Hz, PC), 15.30 (d, J = 7.6 Hz, POCC) ppm; ³¹P NMR (81 MHz, CD₃OD): δ = 33.70 ppm.

Diethyl 2-[2-(5-bromo-3,4-dihydro-2,4-dioxypyrimidin-1(2H)-yl)acetamido]ethoxy]methylphosphonate
(**19d**, C₁₃H₂₁BrN₃O₇P)

The crude product obtained from 0.170 g diethyl (2-aminoethoxy)methylphosphonate (**7d**, 0.805 mmol) and 0.200 g (5-bromouracil-1-yl)acetic acid (**11**, 0.805 mmol) in the presence of 0.154 g EDC \times HCl (0.805 mmol) and 0.112 cm³ TEA (0.805 mmol) according to the general procedure C for 1.0 h was chromatographed with chloroform–methanol mixtures (50:1, 20:1 v/v) and the selected fractions were crystallized from ethyl acetate to give pure compound **19d** (0.172 g, 48% yield) as a white powder. M.p.: 149–151 °C; IR (KBr): $\bar{\nu}$ = 3323, 3107, 2990, 2867, 2820, 2768, 1711, 1669, 1237, 1034, 972 cm⁻¹; ¹H NMR (200 MHz, CD₃OD): δ = 8.04 (s, 1H, HC6), 4.49 (s, 2H, C(O)CH₂), 4.29–4.14 (m, 4H, 2 \times POCH₂CH₃), 3.92 (d, J = 8.5 Hz, 2H, PCH₂O), 3.69 (t, J = 5.3 Hz, 2H, PCH₂OCH₂CH₂), 3.46 (t, J = 5.3 Hz, 2H, POCOCH₂CH₂), 1.38 (t, J = 7.1 Hz, 6H, 2 \times POCH₂CH₃) ppm; ¹³C NMR (151 MHz, CD₃OD): δ = 167.82, 160.77, 150.88, 145.90, 95.06, 71.44 (d, J = 12.0 Hz, PCOC), 64.19 (d, J = 167.6 Hz, PC), 62.80 (d, J = 6.6 Hz, POC), 49.77, 39.00, 15.40 (d, J = 5.6 Hz, POCC) ppm; ³¹P NMR (81 MHz, CD₃OD): δ = 23.11 ppm.

Diethyl [2-(3,4-dihydro-5-methyl-2,4-dioxypyrimidin-1(2H)-yl)acetamido]methylphosphonate
(**20a**, C₁₃H₂₂N₃O₆P)

The crude product obtained from 0.048 g diethyl aminomethylphosphonate (**7a**, 0.287 mmol) and 0.053 g (thymine-1-yl)acetic acid (**12**, 0.287 mmol) in the presence of 0.055 g EDC \times HCl (0.287 mmol) and 0.040 cm³ TEA (0.287 mmol) according to the general procedure C was chromatographed with chloroform–methanol mixtures (50:1, 20:1 v/v) to give pure compound **20a** (0.060 g, 63% yield) as a white powder. M.p.: 211.5–212.5 °C; IR (KBr): $\bar{\nu}$ = 3227, 3058, 2986, 2932, 2833, 1697, 1653, 1242, 1200, 1020 cm⁻¹; ¹H NMR (200 MHz, CD₃OD): δ = 7.41 (q, ⁴ J = 1.2 Hz, 1H, HC6), 4.48 (d, J = 1.5 Hz, 2H, C(O)CH₂), 4.28–4.11 (m, 4H, 2 \times POCH₂CH₃), 3.77 (d, J = 11.8 Hz, 2H, PCH₂), 1.91 (d, ⁴ J = 1.2 Hz, 3H, CH₃), 1.37 (t, J = 6.8 Hz, 6H, 2 \times POCH₂CH₃) ppm; ¹³C NMR (151 MHz, CD₃OD): δ = 168.11 (d, ³ J = 4.2 Hz,

C(O)NHCP), 165.58, 151.57, 142.15, 109.66, 62.80 (d, $J = 6.5$ Hz, POC), 49.39, 34.23 (d, $J = 158.5$ Hz, PC), 15.28 (d, $J = 5.7$ Hz, POCC), 10.78 ppm; ^{31}P NMR (81 MHz, CD_3OD): $\delta = 23.6$ ppm.

Diethyl 2-[2-(3,4-dihydro-5-methyl-2,4-dioxypyrimidin-1(2H)-yl)acetamido]ethylphosphonate (**20b**, $\text{C}_{13}\text{H}_{22}\text{N}_3\text{O}_6\text{P}$)

The crude product obtained from 0.100 g diethyl 2-aminoethylphosphonate (**7b**, 0.550 mmol) and 0.101 g (thymine-1-yl)acetic acid (**12**, 0.550 mmol) in the presence of 0.105 g EDC \times HCl (0.550 mmol) and 0.077 cm^3 TEA (0.55 mmol) according to the general procedure B was chromatographed with chloroform–methanol mixtures (100:1, 50:1, 20:1 v/v) to give pure compound **20b** (0.141 g, 74% yield) as a white powder. M.p.: 196–197 °C; IR (KBr): $\bar{\nu} = 3229, 3161, 3035, 2979, 2930, 2827, 1695, 1651, 1230, 1022$ cm^{-1} ; ^1H NMR (600 MHz, CD_3OD): $\delta = 7.35$ (s, 1H, HC6), 4.37 (s, 2H, C(O)CH₂), 4.16–4.07 (m, 4H, 2 \times POCH₂CH₃), 3.45 (dt, $J = 12.2$ Hz, $J = 7.6$ Hz, 2H, PCH₂CH₂), 2.07 (dt, $J = 18.2$ Hz, $J = 7.6$ Hz, 2H, PCH₂), 1.88 (s, 3H, CH₃), 1.34 (t, $J = 7.1$ Hz, 6H, 2 \times POCH₂CH₃) ppm; ^{13}C NMR (151 MHz, CD_3OD): $\delta = 168.10, 165.57, 151.65, 142.24, 109.71, 62.10$ (d, $J = 6.5$ Hz, POC), 49.68, 33.39 (d, $J = 1.5$ Hz), 24.88 (d, $J = 138.9$ Hz, PC), 15.34 (d, $J = 6.0$ Hz, POCC), 10.82 ppm; ^{31}P NMR (243 MHz, CD_3OD): $\delta = 33.29$ ppm.

Diethyl 3-[2-(3,4-dihydro-5-methyl-2,4-dioxypyrimidin-1(2H)-yl)acetamido]propylphosphonate (**20c**, $\text{C}_{14}\text{H}_{24}\text{N}_3\text{O}_6\text{P} \times 0.5\text{H}_2\text{O}$)

The crude product obtained from 0.050 g diethyl 3-aminopropylphosphonate (**7c**, 0.26 mmol) and 0.047 g (thymine-1-yl)acetic acid (**12**, 0.26 mmol) in the presence of 0.049 g EDC \times HCl (0.26 mmol) and 0.036 cm^3 TEA (0.26 mmol) according to the general procedure B was chromatographed with chloroform–methanol mixtures (50:1, 20:1 v/v) and the selected fractions were crystallized from a methanol–diethyl ether mixture to give pure compound **20c** (0.043 g, 46% yield) as a white solid. M.p.: 183–184 °C; IR (KBr): $\bar{\nu} = 3264, 3158, 3093, 3035, 2982, 2944, 2884, 2830, 1698, 1683, 1238, 1016$ cm^{-1} ; ^1H NMR (600 MHz, CD_3OD): $\delta = 7.38$ (q, $J = 1.3$ Hz, 1H, HC6), 4.40 (s, 2H, C(O)CH₂), 4.16–4.07 (m, 4H, 2 \times POCH₂CH₃), 3.30 (t, $J = 6.9$ Hz, 2H, PCH₂CH₂CH₂), 1.90 (d, $J = 1.3$ Hz, 3H, CH₃), 1.88–1.77 (m, 4H, PCH₂CH₂), 1.35 (t, $J = 7.1$ Hz, 6H, 2 \times POCH₂CH₃) ppm; ^{13}C NMR (151 MHz, CD_3OD): $\delta = 168.26, 165.61, 151.62, 142.25, 109.65, 61.87$ (d, $J = 6.6$ Hz, POC), 49.84, 39.34 (d, $J = 18.1$ Hz, PCCC), 22.13 (d, $J = 4.7$ Hz, PCC), 21.92 (d, $J = 141.9$ Hz, PC), 15.30 (d, $J = 6.2$ Hz, POCC), 10.78 ppm; ^{31}P NMR (243 MHz, CD_3OD): $\delta = 32.78$ ppm.

Diethyl 2-[2-(3,4-dihydro-5-methyl-2,4-dioxypyrimidin-1(2H)-yl)acetamido]ethoxy]methylphosphonate (**20d**, $\text{C}_{14}\text{H}_{24}\text{N}_3\text{O}_7\text{P}$)

The crude product obtained from 0.072 g diethyl (2-aminoethoxy)methylphosphonate (**7d**, 0.34 mmol) and 0.063 g (thymine-1-yl)acetic acid (**12**, 0.34 mmol) in the presence of 0.065 g EDC \times HCl (0.34 mmol) and 0.048 cm^3 TEA (0.34 mmol) according to the general procedure B was chromatographed with chloroform–methanol mixtures (50:1, 20:1 v/v) and the selected fractions were crystallized from ethyl acetate to give pure compound **20d** (0.060 g, 47% yield) as a white solid. M.p.: 116–117 °C; IR (KBr): $\bar{\nu} = 3323, 3151, 3078, 3057, 2982, 2954, 2906, 2837, 1678, 1661, 1236, 1026$ cm^{-1} ; ^1H NMR (200 MHz, CD_3OD): $\delta = 7.40$ (q, $J = 1.1$ Hz, 1H, HC6), 4.44 (s, 2H, C(O)CH₂), 4.29–4.14 (m, 4H, 2 \times POCH₂CH₃), 3.93 (d, $J = 8.5$ Hz, 2H, PCH₂O), 3.69 (t, $J = 5.3$ Hz, 2H, PCH₂OCH₂CH₂), 3.46 (t, $J = 5.3$ Hz, 2H, PCOCH₂CH₂), 1.92 (d, $J = 1.1$ Hz, 3H, CH₃), 1.38 (t, $J = 7.0$ Hz, 6H, 2 \times POCH₂CH₃) ppm; ^{13}C NMR (151 MHz, CD_3OD): $\delta = 168.23, 165.60, 151.62, 142.26, 109.62, 71.45$ (d, $J = 12.1$ Hz, PCOC), 64.17 (d, $J = 167.6$ Hz, PC), 62.78 (d, $J = 6.7$ Hz, POC), 49.54, 38.98, 15.37 (d, $J = 5.6$ Hz, POCC), 10.79 ppm; ^{31}P NMR (81 MHz, CD_3OD): $\delta = 23.10$ ppm.

Diethyl [2-[4-[(benzyloxy)carbonyl]amino]-2-oxypyrimidin-1(2H)-yl]acetamido]methylphosphonate (**21a**, $\text{C}_{19}\text{H}_{25}\text{N}_4\text{O}_7\text{P} \times 0.5\text{H}_2\text{O}$)

The crude product obtained from 0.104 g diethyl aminomethylphosphonate (**7a**, 0.622 mmol) and 0.189 g [*N*⁴-[(benzyloxy)carbonyl]cytosine-1-yl]acetic acid (**13**, 0.622 mmol) in the presence of 0.119 g EDC \times HCl (0.622 mmol) and 0.087 cm^3 TEA (0.62 mmol) according to the general procedure B was chromatographed with chloroform–methanol mixtures (100:1, 50:1, 20:1 v/v) and the selected fractions were crystallized from a methanol–petroleum ether mixture to give pure compound **21a** (0.125 g, 44% yield) as a white solid. M.p.: 180–182 °C; IR (KBr): $\bar{\nu} = 3279, 3147, 3081, 2990, 2949, 2928, 1753, 1657, 1257, 1205, 1025$ cm^{-1} ; ^1H NMR (600 MHz, CDCl_3): $\delta = 9.18$ (brs, 1H, HNCbz), 8.29 (brt, $J = 5.9$ Hz, 1H, HNC(O)), 7.66 (d, $J = 7.1$ Hz, 1H, HC6), 7.41–7.29 (m, 5H), 7.25 (brs, 1H), 5.22 (s, 2H, CH₂C₆H₅), 4.65 (s, 2H, C(O)CH₂), 4.12–4.07 (m, 4H, 2 \times POCH₂CH₃), 3.75 (dd, $J = 11.8$ Hz, $J = 5.9$ Hz, 2H, PCH₂), 1.28 (t, $J = 7.0$ Hz, 6H, 2 \times POCH₂CH₃) ppm; ^{13}C NMR (151 MHz, CDCl_3): $\delta = 166.89$ (d, $J = 4.6$ Hz), 163.24, 156.18, 152.72, 149.37, 135.32, 128.61, 128.50, 128.19, 95.55, 67.70, 62.78 (d, $J = 6.6$ Hz, POC), 52.31, 35.07 (d, $J = 157.5$ Hz, PC), 16.34 (d, $J = 5.6$ Hz, POCC) ppm; ^{31}P NMR (273 MHz, CDCl_3): $\delta = 22.49$ ppm.

Diethyl 2-[2-[4-[[[(benzyloxy)carbonyl]amino]-2-oxopyrimidin-1(2H)-yl]acetamido]ethylphosphonate
(**21b**, C₂₀H₂₇N₄O₇P)

The crude product obtained from 0.111 g diethyl 2-aminoethylphosphonate (**7b**, 0.613 mmol) and 0.186 g [*N*⁴-[(benzyloxy)carbonyl]cytosine-1-yl]acetic acid (**13**, 0.613 mmol) in the presence of 0.117 g EDC × HCl (0.613 mmol) and 0.085 cm³ TEA (0.61 mmol) according to the general procedure B was chromatographed with chloroform–methanol mixtures (100:1, 50:1, 20:1 v/v) to give pure compound **21b** (0.224 g, 78% yield) as a white solid. M.p.: 127–128 °C; IR (KBr): $\bar{\nu}$ = 3241, 3063, 3035, 2982, 2930, 1742, 1657, 1630, 1215, 1056 cm⁻¹; ¹H NMR (600 MHz, CD₃OD): δ = 7.92 (d, *J* = 7.3 Hz, 1H, HC6), 7.44–7.33 (m, 5H), 7.30 (d, *J* = 7.3 Hz, 1H, HC5), 5.25 (s, 2H, CH₂C₆H₅), 4.56 (s, 2H, C(O)CH₂), 4.18–4.08 (m, 4H, 2 × POCH₂CH₃), 3.48 (dt, *J* = 11.7 Hz, *J* = 7.6 Hz, 2H, PCH₂CH₂), 2.11 (dt, *J* = 18.2 Hz, *J* = 7.6 Hz, 2H, PCH₂), 1.35 (t, *J* = 7.1 Hz, 6H, 2 × POCH₂CH₃) ppm; ¹³C NMR (151 MHz, CD₃OD): δ = 167.65, 164.11, 157.08, 153.17, 150.21, 135.80, 128.23, 128.06, 127.89, 95.39, 67.21, 62.08 (d, *J* = 6.5 Hz, POC), 51.96, 33.47, 24.89 (d, *J* = 139.5 Hz, PC), 15.34 (d, *J* = 5.6 Hz, POCC) ppm; ³¹P NMR (243 MHz, CD₃OD): δ = 29.35 ppm.

Diethyl 3-[2-[4-[[[(benzyloxy)carbonyl]amino]-2-oxopyrimidin-1(2H)-yl]acetamido]propylphosphonate
(**21c**, C₂₁H₂₉N₄O₇P)

The crude product obtained from 0.050 g diethyl 3-aminopropylphosphonate (**7c**, 0.26 mmol) and 0.078 g [*N*⁴-[(benzyloxy)carbonyl]cytosine-1-yl]acetic acid (**13**, 0.26 mmol) in the presence of 0.049 g EDC × HCl (0.26 mmol) and 0.036 cm³ TEA (0.26 mmol) according to the general procedure B was chromatographed with chloroform–methanol mixtures (50:1, 20:1 v/v) and the selected fractions were crystallized from an ethyl acetate–hexane mixture to give pure compound **21c** (0.066 g, 54% yield) as white needles. M.p.: 150–151 °C; IR (KBr): $\bar{\nu}$ = 3281, 3239, 3149, 3089, 3038, 2976, 2939, 1749, 1687, 1653, 1225, 1021 cm⁻¹; ¹H NMR (600 MHz, CD₃OD): δ = 7.93 (d, *J* = 7.3 Hz, 1H, HC6), 7.45–7.35 (m, 5H), 7.31 (d, *J* = 7.3 Hz, 1H, HC5), 5.25 (s, 2H, CH₂C₆H₅), 4.56 (s, 2H, C(O)CH₂), 4.16–4.07 (m, 4H, 2 × POCH₂CH₃), 3.32 (t, *J* = 6.5 Hz, 2H, PCH₂CH₂CH₂), 1.90–1.78 (m, 4H, PCH₂CH₂), 1.34 (t, *J* = 7.1 Hz, 6H, 2 × POCH₂CH₃) ppm; ¹³C NMR (151 MHz, CD₃OD): δ = 167.79, 163.99, 157.04, 153.17, 150.28, 135.82, 128.23, 128.06, 127.89, 95.31, 67.20, 61.88 (d, *J* = 6.6 Hz, POC), 52.08, 39.43 (d, *J* = 18.7 Hz, PCCC), 22.12 (d, *J* = 4.9 Hz, PCC), 21.95 (d, *J* = 141.9 Hz, PC), 15.36 (d, *J* = 5.9 Hz, POCC) ppm; ³¹P NMR (243 MHz, CD₃OD): δ = 32.77 ppm.

Diethyl 2-[2-[4-[[[(benzyloxy)carbonyl]amino]-2-oxopyrimidin-1(2H)-yl]acetamido] ethoxy]methylphosphonate
(**21d**, C₂₁H₂₉N₄O₈P)

The crude product obtained from 0.068 g diethyl (2-aminoethoxy)methylphosphonate (**7d**, 0.32 mmol) and 0.098 g [*N*⁴-[(benzyloxy)carbonyl]cytosine-1-yl]acetic acid (**13**, 0.32 mmol) in the presence of 0.062 g EDC × HCl (0.32 mmol) and 0.045 cm³ TEA (0.32 mmol) according to the general procedure B was chromatographed with chloroform–methanol mixtures (50:1, 20:1 v/v) and the selected fractions were crystallized from an ethyl acetate–hexane mixture to give pure compound **21d** (0.073 g, 48% yield) as a white solid. M.p.: 129–131 °C; IR (KBr): $\bar{\nu}$ = 3332, 3145, 3069, 3032, 2981, 2930, 2869, 1751, 1658, 1214, 1022 cm⁻¹; ¹H NMR (200 MHz, CD₃OD): δ = 7.96 (d, *J* = 7.4 Hz, 1H, HC6), 7.50–7.34 (m, 5H), 7.34 (d, *J* = 7.4 Hz, 1H, HC5), 5.27 (s, 2H, CH₂C₆H₅), 4.61 (s, 2H, C(O)CH₂), 4.28–4.14 (m, 4H, 2 × POCH₂CH₃), 3.93 (d, *J* = 8.5 Hz, 2H, PCH₂O), 3.69 (t, *J* = 5.3 Hz, 2H, PCH₂OCH₂CH₂), 3.46 (t, *J* = 5.3 Hz, 2H, PCOCH₂CH₂), 1.38 (t, *J* = 7.0 Hz, 6H, 2 × POCH₂CH₃) ppm; ¹³C NMR (151 MHz, CD₃OD): δ = 167.77, 163.97, 157.06, 153.17, 150.26, 135.82, 128.23, 128.06, 127.89, 95.29, 71.48 (d, *J* = 12.0 Hz, PCOC), 67.21, 64.21 (d, *J* = 166.1 Hz, PC), 62.79 (d, *J* = 6.6 Hz, POC), 51.82, 39.00, 15.41 (d, *J* = 5.8 Hz, POCC) ppm; ³¹P NMR (81 MHz, CD₃OD): δ = 23.10 ppm.

Diethyl [2-(3,4-dihydro-2,4-dioxoquinazolin-1(2H)-yl)acetamido]methylphosphonate
(**22a**, C₁₅H₂₀N₃O₆P × 2H₂O)

The crude product obtained from 0.058 g diethyl aminomethylphosphonate (**7a**, 0.35 mmol) and 0.076 g 2-(3,4-dihydro-2,4-dioxoquinazolin-1-yl)acetic acid (**14**, 0.35 mmol) in the presence of 0.067 g EDC × HCl (0.35 mmol) and 0.048 cm³ TEA (0.35 mmol) according to the general procedure C was chromatographed with chloroform–methanol mixtures (50:1, 20:1 v/v) and the selected fractions were crystallized from a methanol–diethyl ether mixture to give pure compound **22a** (0.086 g, 67% yield) as a white powder. M.p.: 203–205 °C; IR (KBr): $\bar{\nu}$ = 3462, 3264, 3197, 2975, 2909, 1736, 1638, 1044, 1013 cm⁻¹; ¹H NMR (200 MHz, CD₃OD): δ = 8.10–8.05 (m, 1H), 7.75–7.66 (m, 1H), 7.32–7.21 (m, 2H), 4.76 (d, *J* = 1.6 Hz, 2H, C(O)CH₂), 4.27–4.12 (m, 4H, 2 × POCH₂CH₃), 3.78 (d, *J* = 11.8 Hz, 2H, PCH₂), 1.37 (t, *J* = 6.8 Hz, 6H, 2 × POCH₂CH₃) ppm; ¹³C NMR (151 MHz, CD₃OD): δ = 166.47 (d, *J* = 4.0 Hz, C(O)NHCP), 162.72, 150.78, 139.58, 135.05, 127.50, 122.72, 114.90, 113.99, 62.86 (d, *J* = 6.6 Hz, POC), 42.31, 34.23 (d, *J* = 158.4 Hz, PC), 15.30 (d, *J* = 5.6 Hz, POCC) ppm; ³¹P NMR (81 MHz, CD₃OD): δ = 23.56 ppm.

Diethyl 2-[2-(3,4-dihydro-2,4-dioxoquinazolin-1(2H)-yl)acetamido]ethylphosphonate (22b, C₁₆H₂₂N₃O₆P)

The crude product obtained from 0.051 g diethyl 2-aminoethylphosphonate (**7b**, 0.28 mmol) and 0.062 g 2-(3,4-dihydro-2,4-dioxoquinazolin-1-yl)acetic acid (**14**, 0.28 mmol) in the presence of 0.054 g EDC × HCl (0.28 mmol) and 0.039 cm³ TEA (0.28 mmol) according to the general procedure C was chromatographed with chloroform–methanol mixtures (100:1, 50:1, 20:1 v/v) to give pure compound **22b** (0.073 g, 68% yield) as a white powder. M.p.: 180–182 °C; IR (KBr): $\bar{\nu}$ = 3249, 3205, 3083, 2983, 2930, 2882, 1736, 1637, 1027 cm⁻¹; ¹H NMR (600 MHz, CD₃OD): δ = 8.64 (dd, *J* = 7.1 Hz, *J* = 1.3 Hz, 1H), 7.69 (dt, 1H, *J* = 7.1 Hz, *J* = 1.0 Hz), 7.27 (dt, *J* = 8.2 Hz, *J* = 1.0 Hz, 1H), 7.22 (d, *J* = 8.2 Hz, 1H), 4.69 (s, 2H, C(O)CH₂), 4.19–4.09 (m, 4H, 2 × POCH₂CH₃), 3.50–3.46 (m, 2H, PCH₂CH₂), 2.14–2.08 (m, 2H, PCH₂), 1.36 (t, *J* = 7.1 Hz, 6H, 2 × POCH₂CH₃) ppm; ¹³C NMR (151 MHz, CD₃OD): δ = 168.55, 162.76, 150.80, 139.55, 135.04, 127.50, 122.73, 114.90, 113.99, 62.06 (d, *J* = 6.6 Hz, POC), 42.55 (PCC), 33.40, 26.64, 24.91 (d, *J* = 138.9 Hz, PC), 15.32 (d, *J* = 6.0 Hz, POCC) ppm; ³¹P NMR (243 MHz, CD₃OD): δ = 29.51 ppm.

Diethyl 3-[2-(3,4-dihydro-2,4-dioxoquinazolin-1(2H)-yl)acetamido]propylphosphonate (22c, C₁₇H₂₄N₃O₆P)

The crude product obtained from 0.085 g diethyl 3-aminopropylphosphonate (**7c**, 0.435 mmol) and 0.096 g 2-(3,4-dihydro-2,4-dioxoquinazolin-1-yl)acetic acid (**14**, 0.435 mmol) in the presence of 0.083 g EDC × HCl (0.435 mmol) and 0.061 cm³ TEA (0.435 mmol) according to the general procedure B was chromatographed with chloroform–methanol mixtures (50:1, 20:1 v/v) to give pure compound **22c** (0.083 g, 48% yield) as a white powder. M.p.: 168–169 °C; IR (KBr): $\bar{\nu}$ = 3267, 3201, 3148, 3065, 2984, 2928, 1736, 1661, 1638, 1232, 1031 cm⁻¹; ¹H NMR (200 MHz, CD₃OD): δ = 8.07–8.02 (m, 1H), 7.73–7.64 (m, 1H), 7.30–7.17 (m, 2H), 4.70 (s, 2H, C(O)CH₂), 4.23–4.05 (m, 4H, 2 × POCH₂CH₃), 3.33 (t, *J* = 6.5 Hz, 2H, PCH₂CH₂CH₂), 1.98–1.67 (m, 4H, PCH₂CH₂), 1.36 (t, *J* = 7.1 Hz, 6H, 2 × POCH₂CH₃) ppm; ¹³C NMR (151 MHz, CD₃OD): δ = 168.74, 162.82, 150.84, 139.61, 135.01, 127.50, 122.68, 114.88, 114.07, 61.86 (d, *J* = 6.6 Hz, POC), 42.60, 39.24 (d, *J* = 19.0 Hz, PCCC), 22.17 (d, *J* = 4.5 Hz, PCC), 21.85 (d, *J* = 141.9 Hz, PC), 15.30 (d, *J* = 6.3 Hz, POCC) ppm; ³¹P NMR (81 MHz, CD₃OD): δ = 33.86 ppm.

Diethyl 2-[2-(3,4-dihydro-2,4-dioxoquinazolin-1(2H)-yl)acetamido]ethoxy)methylphosphonate (22d, C₁₇H₂₄N₃O₇P)

The crude product obtained from 0.078 g diethyl (2-aminoethoxy)methylphosphonate (**7d**, 0.37 mmol) and

0.061 g 2-(3,4-dihydro-2,4-dioxoquinazolin-1-yl)acetic acid (**14**, 0.37 mmol) in the presence of 0.071 g EDC × HCl (0.37 mmol) and 0.051 cm³ TEA (0.37 mmol) according to the general procedure C was chromatographed with chloroform–methanol mixtures (50:1, 20:1 v/v) to give pure compound **22d** (0.127 g, 83% yield) as a white solid. M.p.: 169–170 °C; IR (KBr): $\bar{\nu}$ = 3196, 3148, 3123, 3065, 2978, 2940, 1737, 1639, 1240, 1028 cm⁻¹; ¹H NMR (200 MHz, CD₃OD): δ = 8.09–8.04 (m, 1H), 7.74–7.66 (m, 1H), 7.32–7.21 (m, 2H), 4.72 (s, 2H, C(O)CH₂), 4.29–4.14 (m, 4H, 2 × POCH₂CH₃), 3.94 (d, *J* = 8.5 Hz, 2H, PCH₂O), 3.70 (t, *J* = 5.3 Hz, 2H, PCH₂OCH₂CH₂), 3.46 (t, *J* = 5.3 Hz, 2H, PCOCH₂CH₂), 1.38 (t, *J* = 7.0 Hz, 3H, POCH₂CH₃) ppm; ¹³C NMR (151 MHz, CD₃OD): δ = 168.64, 162.78, 150.82, 139.58, 135.00, 127.50, 122.69, 114.89, 114.04, 71.55 (d, *J* = 12.1 Hz, PCOC), 64.25 (d, *J* = 166.3 Hz, PC), 62.84 (d, *J* = 6.6 Hz, POC), 42.47, 39.00, 15.39 (d, *J* = 5.6 Hz, POCC) ppm; ³¹P NMR (81 MHz, CD₃OD): δ = 23.08 ppm.

Diethyl [2-[6-(bis(tert-butoxycarbonyl)amino)-9H-purin-9-yl]acetamido]methylphosphonate (23a, C₂₂H₃₅N₆O₈P)

The crude product obtained from 0.109 g diethyl aminomethylphosphonate (**7a**, 0.622 mmol) and 0.256 g 2-[6-[bis(tert-butoxycarbonyl)amino]-9H-purin-9-yl]acetic acid (**15**, 0.622 mmol) in the presence of 0.125 g EDC × HCl (0.622 mmol) and 0.091 cm³ TEA (0.62 mmol) according to the general procedure B was chromatographed with chloroform–methanol mixtures (100:1, 50:1, 20:1 v/v) and the selected fractions were crystallized from a methanol–petroleum ether mixture to give pure compound **23a** (0.183 g, 52% yield) as a white solid. M.p.: 128–130 °C; IR (KBr): $\bar{\nu}$ = 3256, 3109, 2980, 2934, 1735, 1699, 1672, 1049 cm⁻¹; ¹H NMR (600 MHz, CD₃OD): δ = 8.85 (s, 1H), 8.54 (s, 1H), 5.19 (s, 2H, C(O)CH₂), 4.19–4.14 (m, 4H, 2 × POCH₂CH₃), 3.78 (d, *J* = 11.8 Hz, 2H, PCH₂), 1.41 (s, 18H, 6 × CH₃), 1.33 (t, *J* = 7.0 Hz, 6H, 2 × POCH₂CH₃) ppm; ¹³C NMR (151 MHz, CD₃OD): δ = 166.75 (d, *J* = 4.4 Hz, C(O)NHCP), 153.84, 151.66, 150.14, 149.47, 147.72, 128.37, 83.91, 62.81 (d, *J* = 6.5 Hz, POC), 45.14, 34.41 (d, *J* = 158.6 Hz, PC), 26.65, 15.36 (d, *J* = 5.7 Hz, POCC) ppm; ³¹P NMR (243 MHz, CD₃OD): δ = 22.68 ppm.

Diethyl 2-[2-[6-(bis(tert-butoxycarbonyl)amino)-9H-purin-9-yl]acetamido]ethylphosphonate (23b, C₂₃H₃₇N₆O₈P × 0.5 H₂O)

The crude product obtained from 0.108 g diethyl 2-aminoethylphosphonate (**7b**, 0.596 mmol) and 0.235 g 2-[6-[bis(tert-butoxycarbonyl)amino]-9H-purin-9-yl]acetic acid (**15**, 0.596 mmol) in the presence of 0.114 g EDC × HCl (0.596 mmol) and 0.083 cm³ TEA

(0.60 mmol) according to the general procedure B was chromatographed with chloroform–methanol mixtures (100:1, 50:1, 20:1 v/v) to give pure compound **23b** (0.155 g, 47% yield) as a colorless oil. IR (film): $\bar{\nu} = 3356, 3284, 3085, 2983, 2936, 1788, 1760, 1697, 1251, 1027 \text{ cm}^{-1}$; $^1\text{H NMR}$ (200 MHz, CD_3OD): $\delta = 8.87$ (s, 1H), 8.56 (s, 1H), 5.14 (s, 2H, $\text{C}(\text{O})\text{CH}_2$), 4.25–4.07 (m, 4H, $2 \times \text{POCH}_2\text{CH}_3$), 3.60–3.48 (m, 2H, PCH_2CH_2), 2.22–2.06 (m, 2H, 2H, PCH_2), 1.43 (s, 18H, $6 \times \text{CH}_3$), 1.37 (t, $J = 7.1 \text{ Hz}$, 6H, $2 \times \text{POCH}_2\text{CH}_3$) ppm; $^{13}\text{C NMR}$ (151 MHz, CD_3OD): $\delta = 166.73, 153.85, 151.65, 150.17, 149.46, 147.72, 128.37, 83.91, 62.08$ (d, $J = 6.6 \text{ Hz}$, POC), 45.26, 33.57, 26.64, 24.89 (d, $J = 138.9 \text{ Hz}$, PC), 15.37 (d, $J = 5.7 \text{ Hz}$, POCC) ppm; $^{31}\text{P NMR}$ (81 MHz, CD_3OD): $\delta = 30.17 \text{ ppm}$.

Diethyl 3-[2-[6-(bis(tert-butoxycarbonyl)amino-9H-purin-9-yl)acetamido]propylphosphonate (**23c**, $\text{C}_{24}\text{H}_{39}\text{N}_6\text{O}_8\text{P} \times 0.5\text{H}_2\text{O}$)

The crude product obtained from 0.059 g diethyl 3-aminopropylphosphonate (**15**, 0.30 mmol) and 0.119 g 2-[6-[bis(tert-butoxycarbonyl)amino]-9H-purin-9-yl]acetic acid (**15**, 0.302 mmol) in the presence of 0.058 g EDC \times HCl (0.30 mmol) and 0.042 cm^3 TEA (0.30 mmol) according to the general procedure B was chromatographed with chloroform–methanol mixtures (100:1 v/v) to give pure compound **23c** (0.072 g, 42% yield) as a yellowish oil. IR (film): $\bar{\nu} = 3363, 3281, 3087, 2983, 2937, 1788, 1693, 1220, 1024 \text{ cm}^{-1}$; $^1\text{H NMR}$ (600 MHz, CD_3OD): $\delta = 8.85$ (s, 1H), 8.53 (s, 1H), 5.12 (s, 2H, $\text{C}(\text{O})\text{CH}_2$), 4.17–4.07 (m, 4H, $2 \times \text{POCH}_2\text{CH}_3$), 3.36 (t, $J = 6.5 \text{ Hz}$, 2H, $\text{PCH}_2\text{CH}_2\text{CH}_2$), 1.92–1.78 (m, 4H, PCH_2CH_2), 1.42 (s, 18H, $6 \times \text{CH}_3$), 1.34 (t, $J = 7.0 \text{ Hz}$, 6H, $2 \times \text{POCH}_2\text{CH}_3$) ppm; $^{13}\text{C NMR}$ (151 MHz, CD_3OD): $\delta = 166.90, 153.82, 151.65, 150.16, 149.46, 147.73, 128.43, 83.92, 61.88$ (d, $J = 6.6 \text{ Hz}$, POC), 45.42, 39.50 (d, $J = 19.6 \text{ Hz}$, PCCC), 26.61, 22.14 (d, $J = 4.6 \text{ Hz}$, PCC), 22.00 (d, $J = 142.6 \text{ Hz}$, PC), 15.33 (d, $J = 5.6 \text{ Hz}$, POCC) ppm; $^{31}\text{P NMR}$ (243 MHz, CD_3OD): $\delta = 32.68 \text{ ppm}$.

Diethyl 2-[2-[6-(bis(tert-butoxycarbonyl)amino-9H-purin-9-yl)acetamido]ethoxy)methyl]phosphonate (**23d**, $\text{C}_{24}\text{H}_{39}\text{N}_6\text{O}_9\text{P} \times 0.5\text{H}_2\text{O}$)

The crude product obtained from 0.070 g diethyl (2-aminoethoxy)methylphosphonate (**7d**, 0.33 mmol) and 0.130 g 2-[6-[bis(tert-butoxycarbonyl)amino]-9H-purin-9-yl]acetic acid (**15**, 0.33 mmol) in the presence of 0.064 g EDC \times HCl (0.33 mmol) and 0.046 cm^3 TEA (0.33 mmol) according to the general procedure B was chromatographed with chloroform–methanol mixtures (100:1, 50:1 v/v) to give pure compound **23d** (0.102 g, 52% yield) as a colorless oil. IR (film): $\bar{\nu} = 3282, 3086, 2982, 2935, 1786, 1757, 1220, 1028 \text{ cm}^{-1}$; $^1\text{H NMR}$

(200 MHz, CDCl_3): $\delta = 8.83$ (s, 1H), 8.26 (s, 1H), 7.69 (t, $J = 6.0 \text{ Hz}$, 1H, $\text{C}(\text{O})\text{NHCH}_2$), 4.96 (s, 2H, $\text{C}(\text{O})\text{CH}_2$), 4.29–4.10 (m, 4H, $2 \times \text{POCH}_2\text{CH}_3$), 3.82 (d, $J = 7.9 \text{ Hz}$, 2H, PCH_2O), 3.70 (t, $J = 4.6 \text{ Hz}$, 2H, $\text{PCH}_2\text{OCH}_2\text{CH}_2$), 3.50 (t, $J = 4.6 \text{ Hz}$, 2H, $\text{PCOCH}_2\text{CH}_2$), 1.43 (s, 18 H, $6 \times \text{CH}_3$), 1.35 (t, $J = 7.1 \text{ Hz}$, 6H, $2 \times \text{POCH}_2\text{CH}_3$) ppm; $^{13}\text{C NMR}$ (151 MHz, CDCl_3): $\delta = 165.64, 153.53, 152.02, 150.43, 150.34, 145.63, 128.44, 83.72, 72.22$ (d, $J = 8.8 \text{ Hz}$, PCOC), 65.59 (d, $J = 166.8 \text{ Hz}$, PC), 62.69 (d, $J = 6.7 \text{ Hz}$, POC), 46.07, 39.76, 27.79, 16.46 (d, $J = 5.5 \text{ Hz}$, POCC) ppm; $^{31}\text{P NMR}$ (81 MHz, CDCl_3): $\delta = 22.77 \text{ ppm}$.

Diethyl [2-(2-amino-6-chloro-9H-purin-9-yl)-acetamido]methylphosphonate (**24a**, $\text{C}_{12}\text{H}_{18}\text{ClN}_6\text{O}_4\text{P} \times 0.5\text{H}_2\text{O}$)

The crude product obtained from 0.419 g diethyl aminomethylphosphonate (**7a**, 2.51 mmol) and 0.571 g 2-(2-amino-6-chloropurin-9-yl)acetic acid (**16**, 2.51 mmol) in the presence of 0.481 g EDC \times HCl (2.51 mmol) and 0.358 cm^3 TEA (2.51 mmol) according to the general procedure C was chromatographed with chloroform–methanol mixtures (50:1, 20:1 v/v) and the selected fractions were crystallized from a methanol–diethyl ether mixture to give pure compound **24a** (0.211 g, 22% yield) as a white solid. M.p.: 130–132 °C; IR (KBr): $\bar{\nu} = 3397, 3340, 3221, 3111, 3065, 2987, 2946, 1684, 1610, 1562, 1219, 1053, 1013 \text{ cm}^{-1}$; $^1\text{H NMR}$ (200 MHz, CD_3OD): $\delta = 8.11$ (s, 1H), 4.95 (d, $J = 1.4 \text{ Hz}$, 2H, $\text{C}(\text{O})\text{CH}_2$), 4.21–4.10 (m, 4H, $2 \times \text{POCH}_2\text{CH}_3$), 3.78 (d, $J = 11.8 \text{ Hz}$, 2H, PCH_2), 1.34 (t, $J = 7.0 \text{ Hz}$, 3H, POCH_2CH_3) ppm; $^{13}\text{C NMR}$ (151 MHz, CD_3OD): $\delta = 167.18$ (d, $J = 3.5 \text{ Hz}$), 160.32, 154.18, 150.17, 143.84, 123.22, 62.80 (d, $J = 6.6 \text{ Hz}$, POC), 44.82, 34.37 (d, $J = 158.6 \text{ Hz}$, PC), 15.26 (d, $J = 6.0 \text{ Hz}$, POCC) ppm; $^{31}\text{P NMR}$ (81 MHz, CD_3OD): $\delta = 23.56 \text{ ppm}$.

Diethyl 2-[2-(2-amino-6-chloro-9H-purin-9-yl)-acetamido]ethylphosphonate (**24b**, $\text{C}_{13}\text{H}_{20}\text{ClN}_6\text{O}_4\text{P}$)

The crude product obtained from 0.307 g diethyl 2-aminoethylphosphonate (**7b**, 1.69 mmol) and 0.386 g 2-(2-amino-6-chloropurin-9-yl)acetic acid (**16**, 1.69 mmol) in the presence of 0.325 g EDC \times HCl (1.69 mmol) and 0.236 cm^3 TEA (1.69 mmol) according to the general procedure C was chromatographed with chloroform–methanol mixtures (50:1, 30:1, 10:1 v/v) and the selected fractions were crystallized from a methanol–diethyl ether mixture to give pure compound **24b** (0.126 g, 19% yield) as a white solid. M.p.: 158–160 °C; IR (KBr): $\bar{\nu} = 3411, 3322, 3275, 3122, 3074, 2985, 2929, 1688, 1254, 1030 \text{ cm}^{-1}$; $^1\text{H NMR}$ (600 MHz, CD_3OD): $\delta = 8.05$ (s, 1H), 4.84 (s, 2H, $\text{C}(\text{O})\text{CH}_2$), 4.13–4.09 (m, 4H, $2 \times \text{POCH}_2\text{CH}_3$), 3.48–3.44 (m, 2H, PCH_2CH_2), 2.10–2.06 (m, 2H, 2H, PCH_2), 1.32 (t, $J = 7.0 \text{ Hz}$, 6H,

$2 \times \text{POCH}_2\text{CH}_3$) ppm; ^{13}C NMR (151 MHz, CD_3OD): $\delta = 171.14, 164.26, 158.13, 154.12, 147.78, 127.21, 66.02$ (d, $J = 6.0$ Hz, POC), $48.96, 37.43$ (d, $J = 1.7$ Hz), 28.80 (d, $J = 138.9$ Hz, PC), 19.24 (d, $J = 6.1$ Hz, POCC) ppm; ^{31}P NMR (243 MHz, CD_3OD): $\delta = 33.23$ ppm.

Diethyl 3-[2-(2-amino-6-chloro-9H-purin-9-yl)-acetamido]propylphosphonate (24c, C₂₄H₃₉N₆O₈P)

The crude product obtained from 0.203 g diethyl 3-aminopropylphosphonate (**7c**, 1.04 mmol) and 0.237 g 2-(2-amino-6-chloropurin-9-yl)acetic acid (**16**, 1.04 mmol) in the presence of 0.199 g EDC \times HCl (1.04 mmol) and 0.145 cm³ TEA (1.04 mmol) according to the general procedure C was chromatographed with dichloromethane–methanol mixtures (50:1, 20:1, 10:1 v/v) and the selected fractions were crystallized from an ethanol–ethyl acetate mixture to give pure compound **24c** (0.106 g, 25% yield) as a white solid. M.p.: 180–181 °C; IR (KBr): $\bar{\nu} = 3408, 3343, 3273, 3090, 2988, 2945, 2908, 2869, 1680, 1644, 1608, 1215, 1040$ cm⁻¹; ^1H NMR (600 MHz, CD_3OD): $\delta = 8.07$ (s, 1H), 4.87 (s, 2H, C(O)CH₂), 4.15 – 4.06 (m, 4H, $2 \times \text{POCH}_2\text{CH}_3$), 3.33 (t, $J = 6.5$ Hz, 2H, PCH₂CH₂CH₂), 1.88 – 1.77 (m, 4H, PCH₂CH₂), 1.33 (t, $J = 7.0$ Hz, 6H, $2 \times \text{POCH}_2\text{CH}_3$) ppm; ^{13}C NMR (151 MHz, CD_3OD): $\delta = 167.34, 160.31, 154.19, 150.17, 143.87, 123.32, 61.90$ (d, $J = 6.7$ Hz, POC), $45.15, 39.41$ (d, $J = 19.6$ Hz, PCCC), $26.61, 22.11$ (d, $J = 4.9$ Hz, PCC), 21.98 (d, $J = 142.1$ Hz, PC), 15.30 (d, $J = 6.0$ Hz, POCC) ppm; ^{31}P NMR (243 MHz, CD_3OD): $\delta = 32.75$ ppm.

Diethyl 2-[2-(2-amino-6-chloro-9H-purin-9-yl)acetamido]ethoxymethylphosphonate (24d, C₁₄H₂₂ClN₆O₅P)

The crude product obtained from 0.200 g diethyl (2-aminoethoxy)methylphosphonate (**7d**, 0.947 mmol) and 0.216 g 2-(2-amino-6-chloropurin-9-yl)acetic acid (**16**, 0.947 mmol) in the presence of 0.182 g EDC \times HCl (0.947 mmol) and 0.132 cm³ TEA (0.947 mmol) according to the general procedure C was chromatographed with chloroform–methanol mixtures (50:1, 30:1 v/v) and the selected fractions were crystallized from an ethyl acetate–hexane mixture to give pure compound **24d** (0.048 g, 15% yield) as a white solid. M.p.: 91–93 °C; IR (KBr): $\bar{\nu} = 3430, 3335, 3220, 3095, 2981, 2938, 1650, 1611, 1245, 1024, 910$ cm⁻¹; ^1H NMR (200 MHz, CD_3OD): $\delta = 8.10$ (s, 1H), 4.92 (s, 2H, C(O)CH₂; superimposed in the HOD signal), 4.28 – 4.13 (m, 4H, $2 \times \text{POCH}_2\text{CH}_3$), 3.92 (d, $J = 8.6$ Hz, 2H, PCH₂O), 3.70 (t, $J = 5.3$ Hz, 2H, PCH₂OCH₂CH₂), 3.47 (t, $J = 5.3$ Hz, 2H, PCOCH₂CH₂), 1.37 (t, $J = 7.1$ Hz, 6H, $2 \times \text{POCH}_2\text{CH}_3$) ppm; ^{13}C NMR (151 MHz, CD_3OD): $\delta = 167.33, 160.30, 154.21, 150.14, 143.92, 123.25, 71.42$ (d, $J = 12.1$ Hz, PCOC), 64.18 (d, $J = 167.6$ Hz, PC), 62.77 (d, $J = 6.6$ Hz, POC), $44.96, 39.04, 15.36$ (d, $J = 5.5$ Hz, POCC) ppm; ^{31}P NMR (81 MHz, CD_3OD): $\delta = 23.11$ ppm.

Synthesis of the guanine derivatives 25a–25d (general procedure)

A mixture of phosphonates **24a–24d** (1.00 mmol) and 8 cm³ of a 75% aqueous trifluoroacetic acid was stirred at room temperature for 48 h, concentrated in vacuo and co-evaporated with water (3×5 cm³), ethanol (3×5 cm³), and chloroform (3×5 cm³). The residue was crystallized from the appropriate solvent.

Diethyl [2-(2-amino-1,6-dihydro-6-oxopurin-9-yl)acetamido]methylphosphonate (25a, C₁₂H₁₉N₆O₅P \times 2.5H₂O)

From 0.112 g of compound **24a** (0.297 mmol) the phosphonate **25a** (0.087 g, 81%) was obtained as a white solid after crystallization from a methanol–diethyl ether mixture. M.p.: 165 °C (decomposition); IR (KBr): $\bar{\nu} = 3425, 2988, 2928, 2854, 2732, 1697, 1214, 1026$ cm⁻¹; ^1H NMR (600 MHz, DMSO-*d*₆): $\delta = 10.63$ (s, 1H, NH), 8.61 (t, $J = 5.9$ Hz, 1H, C(O)NHCH₂), 7.73 (s, 1H), 6.47 (s, 2H, NH₂), 4.72 (s, 2H, C(O)CH₂), 4.06 – 3.98 (m, 4H, $2 \times \text{POCH}_2\text{CH}_3$), 3.60 (dd, $J = 11.8$ Hz, $J = 5.9$ Hz, 2H, PCH₂), 1.24 (t, $J = 7.0$ Hz, 6H, $2 \times \text{POCH}_2\text{CH}_3$) ppm; ^{13}C NMR (151 MHz, DMSO-*d*₆): $\delta = 166.96$ (d, $J = 4.5$ Hz), $156.98, 154.22, 151.84, 138.76, 115.84, 62.35$ (d, $J = 6.0$ Hz, POC), $45.24, 34.69$ (d, $J = 154.0$ Hz, PC), 16.70 (d, $J = 6.0$ Hz, POCC) ppm; ^{31}P NMR (243 MHz, DMSO-*d*₆): $\delta = 22.46$ ppm.

Diethyl 2-[2-(2-amino-1,6-dihydro-6-oxopurin-9-yl)acetamido]ethylphosphonate (25b, C₁₃H₂₁N₆O₅P \times H₂O)

From 0.127 g of compound **24b** (0.325 mmol) the phosphonate **25b** (0.109 g, 90%) was obtained as a white solid after crystallization from a methanol–diethyl ether mixture. M.p.: 175 °C (decomposition); IR (KBr): $\bar{\nu} = 3383, 2925, 2854, 1688, 1606, 1220, 1026$ cm⁻¹; ^1H NMR (600 MHz, DMSO-*d*₆): $\delta = 10.73$ (s, 1H, NH), 8.35 (t, $J = 5.5$ Hz, 1H, C(O)NHCH₂), 7.73 (s, 1H), 6.58 (s, 2H, NH₂), 4.63 (s, 2H, C(O)CH₂), 4.03 – 3.95 (m, 4H, $2 \times \text{POCH}_2\text{CH}_3$), 3.30 – 3.24 (m, 2H, PCH₂CH₂), 1.98 – 1.91 (m, 2H, 2H, PCH₂), 1.24 (t, $J = 7.0$ Hz, 6H, $2 \times \text{POCH}_2\text{CH}_3$) ppm; ^{13}C NMR (151 MHz, DMSO-*d*₆): $\delta = 166.78, 157.00, 154.31, 151.82, 138.68, 116.03, 61.62$ (d, $J = 4.5$ Hz, POC), $45.45, 33.77, 25.72$ (d, $J = 136.2$ Hz, PC), 16.71 (d, $J = 5.7$ Hz, POCC) ppm; ^{31}P NMR (81 MHz, DMSO-*d*₆): $\delta = 30.12$ ppm.

Diethyl 3-[2-(2-amino-1,6-dihydro-6-oxopurin-9-yl)acetamido]propylphosphonate (25c, C₁₄H₂₃N₆O₅P \times 2H₂O)

From 0.050 g of compound **24c** (0.12 mmol) the phosphonate **25c** (0.042 g, 87%) was obtained as a white solid after crystallization from a methanol–diethyl ether–petroleum ether mixture. M.p.: 155 °C (decomposition); IR (KBr): $\bar{\nu} = 3385, 3277, 2928, 2864, 1689, 1609, 1228,$

1020 cm^{-1} ; ^1H NMR (600 MHz, $\text{DMSO-}d_6$): δ = 10.91 (s, 1H, NH), 8.29 (t, J = 5.5 Hz, 1H, C(O)NHCH_2), 8.06 (s, 1H), 6.68 (s, 2H, NH_2), 4.70 (s, 2H, C(O)CH_2), 4.04–3.95 (m, 4H, $2 \times \text{POCH}_2\text{CH}_3$), 3.33 (dd, J = 12.7 Hz, J = 6.5 Hz, 2H, $\text{PCH}_2\text{CH}_2\text{CH}_2$), 1.79–1.70 (m, 2H, PCH_2CH_2), 1.67–1.58 (m, 2H, PCH_2CH_2), 1.24 (t, J = 7.0 Hz, 6H, $2 \times \text{POCH}_2\text{CH}_3$) ppm; ^{13}C NMR (151 MHz, $\text{DMSO-}d_6$): δ = 166.36, 156.24, 154.69, 151.53, 138.77, 113.98, 61.42 (d, J = 6.4 Hz, POC), 45.74, 39.62 (d, J = 18.3 Hz, PCCC), 22.80 (d, J = 4.5 Hz, PCC), 22.65 (d, J = 140.4 Hz, PC), 16.74 (d, J = 4.5 Hz, POCC) ppm; ^{31}P NMR (243 MHz, $\text{DMSO-}d_6$): δ = 31.64 ppm.

Diethyl 2-[2-(2-amino-1,6-dihydro-6-oxopurin-9-yl)acetamido]ethoxy)methyl)phosphonate
(**25d**, $\text{C}_{14}\text{H}_{23}\text{N}_6\text{O}_6\text{P} \times \text{H}_2\text{O}$)

From 0.012 g of compound **24d** (0.029 mmol) the phosphonate **25d** (0.010 g, 83%) was obtained as a yellowish oil. IR (film): $\bar{\nu}$ = 3378, 3288, 2938, 2881, 1690, 1611, 1225, 1018 cm^{-1} ; ^1H NMR (600 MHz, $\text{DMSO-}d_6$): δ = 10.64 (s, 1H), 8.28 (t, J = 5.6 Hz, 1H), 7.80 (brs, 1H), 6.50 (s, 2H), 4.66 (s, 2H, C(O)CH_2), 4.08–4.03 (m, 4H, $2 \times \text{POCH}_2\text{CH}_3$), 3.83 (d, J = 8.0 Hz, 2H, PCH_2O), 3.56 (t, J = 5.7 Hz, 2H, $\text{PCH}_2\text{OCH}_2\text{CH}_2$), 3.27 (q, J = 5.7 Hz, 2H, $\text{PCOCH}_2\text{CH}_2$), 1.25 (t, J = 7.0 Hz, 6H, $2 \times \text{POCH}_2\text{CH}_3$) ppm; ^{13}C NMR (151 MHz, $\text{DMSO-}d_6$): δ = 166.87, 156.96, 154.28, 150.14, 138.78, 115.52, 71.44 (d, J = 11.0 Hz, PCOC), 64.50 (d, J = 162.9 Hz, PC), 62.23 (d, J = 6.3 Hz, POC), 45.44, 39.02, 16.75 (d, J = 5.2 Hz, POCC) ppm; ^{31}P NMR (243 MHz, $\text{DMSO-}d_6$): δ = 21.45 ppm.

Antiviral activity assays

The compounds were evaluated against the following viruses: herpes simplex virus type 1 (HSV-1) strain KOS, herpes simplex virus-2 strain G, thymidine kinase-deficient (TK^-) HSV-1 KOS strain resistant to ACV (ACV^r), adenovirus-2, vesicular stomatitis virus, varicella-zoster virus (VZV) strain Oka, TK^- VZV strain 07-1, human cytomegalovirus (HCMV) strains AD-169 and Davis, feline herpes virus (FHV), vaccinia virus Lederle strain, respiratory syncytial virus (RSV) strain Long, vesicular stomatitis virus (VSV), feline coronavirus (FIPV), Coxsackie B4, Parainfluenza 3, Influenza virus A (subtypes H1N1, H3N2), influenza virus B, Reovirus-1, Sindbis, Reovirus-1, Punta Toro, yellow fever virus. The antiviral, other than anti-HIV, assays were based on inhibition of virus-induced cytopathicity or plaque formation in human embryonic lung (HEL) fibroblasts, African green monkey cells (Vero), human epithelial cells (HeLa), Crandell–Rees feline kidney cells (CRFK) or Madin–Darby canine kidney cells (MDCK). Confluent cell cultures in microtiter 96-well

plates were inoculated with 100 CCID₅₀ of virus (1 CCID₅₀ being the virus dose to infect 50% of the cell cultures) or with 20 plaque forming units (PFU) (VZV) in the presence of varying concentrations of the test compounds. Viral cytopathicity or plaque formation was recorded as soon as it reached completion in the control virus-infected cell cultures that were not treated with the test compounds. Antiviral activity was expressed as the EC₅₀ or compound concentration required to reduce virus-induced cytopathogenicity or viral plaque formation by 50%. Cytotoxicity of the test compounds was expressed as the minimum cytotoxic concentration (MCC) or the compound concentration that caused a microscopically detectable alteration of cell morphology.

Cytostatic activity assays

All assays were performed in 96-well microtiter plates. To each well were added $(5\text{--}7.5) \times 10^4$ tumor cells and a given amount of the test compound. The cells were allowed to proliferate for 48 h (murine leukemia L1210 cells) or 72 h (human lymphocytic CEM and human cervix carcinoma HeLa cells) at 37 °C in a humidified CO₂-controlled atmosphere. At the end of the incubation period, the cells were counted in a Coulter counter. The IC₅₀ (50% inhibitory concentration) was defined as the concentration of the compound that inhibited cell proliferation by 50%.

Acknowledgements Financial supports from the National Science Centre (Grant UMO-2013/09/B/NZ7/00729—synthetic part of the project) and the KU Leuven (GOA 15/19 TBA—biological screening) are gratefully acknowledged. The Faculty of Pharmacy authors wish to express their gratitude to Mrs. Jolanta Płocka and Mrs. Małgorzata Pluskota for excellent technical assistance. Special thanks are forwarded to the Rega Institute collaborators: Mrs. Leentje Persoons, Mrs. Frieda De Meyer, Mrs. Ellen De Waegenaere and Mrs. Lizette van Berckelaer.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. De Clercq E (2007) *Biochem Pharmacol* 73:911
2. De Clercq E (2013) *Med Res Rev* 33:1278
3. De Clercq E, Holy A (2005) *Nat Rev Drug Discov* 4:928
4. Magee WC, Evans DH (2012) *Antiviral Res* 96:169
5. Holm L, Bockermann R, Wellner E, Baecklund J, Holmdahl R, Kihlberg J (2006) *Bioorg Med Chem* 14:5921
6. Blomberg D, Kreye P, Fowler CS, Brickmann K, Kihlberg J (2006) *Org Biomol Chem* 4:416

7. Hedenström M, Yuan ZQ, Brickmann K, Carlsson J, Ekholm K, Johansson B, Kreutz E, Nilsson A, Sethson I, Kihlberg J (2002) *J Med Chem* 45:2501
8. Peyman A, Uhlmann E, Wagner K, Augustin S, Breipohl G, Will DW, Schaefer A, Wallmeier H (1996) *Angew Chem Int Ed* 35:2636
9. Kehler J, Henriksen U, Vejbjerg H, Dahl O (1998) *Bioorg Med Chem* 6:315
10. van der Laan AC, Havenaar P, Oosting RS, Kuyl-Yeheskiely E, Uhlmann E, van Boom JH (1998) *Bioorg Med Chem Lett* 8:663
11. Efimov VA, Buryakova AA, Choob MV, Chakhmakheva G (1998) *Bioorg Khim* 24:696
12. Kalman FK, Woods M, Caravan P, Jurek P, Spiller M, Tircso G, Kiraly R, Bruecher E, Sherry AD (2007) *Inorg Chem* 46:5260
13. Gali H, Prabhu KR, Karra SR, Katti KV (2000) *J Org Chem* 65:676
14. Koszytkowska-Stawinska M, De Clercq E, Balzarini J (2009) *Bioorg Med Chem* 17:3756
15. Wheeler HL, Liddle LM (1908) *J Am Chem Soc* 30:1152
16. Tada M (1975) *Bull Chem Soc Jpn* 48:3427
17. Ferrer E, Shevchenko A, Eritja R (2000) *Bioorg Med Chem* 8:291
18. Rabinowitz JL, Gurin S (1953) *J Am Chem Soc* 75:5758
19. Li P, Zhan C, Zhang S, Ding X, Guo F, He S, Yao J (2012) *Tetrahedron* 68:8908
20. Katritzky AR, Narindoshvili T (2008) *Org Biomol Chem* 6:3171
21. Wojciechowski F, Hudson RHE (2008) *J Org Chem* 73:3807
22. Schwergold C, Depecker G, Di Giorgio C, Patino N, Jossinet F, Ehresmann B, Terreux R, Cabrol-Bass D, Condom R (2002) *Tetrahedron* 58:5675
23. Joullié MM, Lassen KM (2010) *Arkivoc* viii:189
24. El-Faham A, Albericio F (2011) *Chem Rev* 111:6557
25. Dunetz JR, Magano J, Weisenburger GA (2016) *Org Process Res Dev* 20:140
26. Falkiewicz B (1999) *Nucleic Acids Symp Ser* 42:153
27. Noel O, Xie J (2013) *Synthesis* 45:134
28. De Cola C, Manicardi A, Corradini R, Izzo I, De Riccardis F (2012) *Tetrahedron* 68:499
29. MacMillan DS, Murray J, Sneddon HF, Craig J, Watson AJB (2013) *Green Chem* 15:596
30. Basavaprabhu, Vishwanatha TM, Panguluri NR, Sureshbabu VV (2013) *Synthesis* 45:1569
31. Sheehan JC, Preston J, Cruickshank PA (1965) *J Am Chem Soc* 87:2492
32. Nozaki S (1999) *J Pept Res* 54:162
33. Doboszewski B, Groaz E, Herdewijn P (2013) *Eur J Org Chem* 2013:4804
34. Hockova D, Keough DT, Janeba Z, Wang TH, de Jersey J, Guddat LW (2012) *J Med Chem* 55:6209
35. Pan X, Wang C, Wang F, Hu Z, Shan Y, Zhang J (2011) *Curr Med Chem* 18:4538
36. Pischel H, Holy A, Vesely J, Wagner G, Cech D (1982) *Coll Czech Chem Commun* 47:2806
37. Wiemer AJ, Wiemer DF (2015) *Top Curr Chem* 360:115